Journal of Clinical Oncology
Articles in this Issue
Identification of nutritional risk in chimeric antigen receptor T-cell (CAR-T) therapy: Protein-energy malnutrition and its impact on patient outcomes.
12158 Background: Protein-energy malnutrition (PEM), an imbalance between protein and energy intake and the body’s require...
Pan-cancer computational analysis of adaptive immune and vascular changes in primary versus metastatic tumors.
3124 Background: Metastasis drives cancer mortality, yet tumor microenvironment (TME) evolution during systemic spread rem...
Value of risk-directed thromboprophylaxis in ambulatory lung and gastrointestinal cancer care: Economic evaluation of the TARGET-TP randomized trial.
12137 Background: Thromboembolism (TE) is a major and preventable hematological complication in patients with cancer, cont...
SPARK-Lung: A study of patterns and outcomes in young-onset lung cancer.
8070 Background: Young onset lung cancer patients diagnosed before age 50 appear to have distinct features compared to the...
GLP-1 therapy and hormone receptor–positive breast cancer risk and survival: A real-world analysis.
10548 Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly used for weight management and ca...
Real-world risk of interstitial lung disease and pneumonitis with trastuzumab deruxtecan vs trastuzumab in HER2-positive metastatic breast cancer: A propensity score–matched analysis.
e13030 Background: HER2-targeted antibody–drug conjugates (ADCs), such as trastuzumab deruxtecan (T-DXd), have substantial...
Molecular analysis of aggressive disease and treatment response in recurrent/metastatic head and neck squamous cell carcinoma.
e18033 Background: Immunotherapy (IO), alone or with chemotherapy, is standard first-line treatment for recurrent/metastat...
Novel transposon BAFF CAR-T cells (LMY-920) for non-Hodgkin lymphoma (NHL).
2563 Background: CAR-T cells targeting CD19 using scFv-based CARs have been effective and approved to treat lymphoma. Resp...
Enfortumab vedotin plus pembrolizumab (EV+P) vs chemotherapy for previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): 3.5-year follow-up and response analyses from the phase 3 EV-302 study.
4507 Background: EV+P is the preferred standard of care for previously untreated la/mUC based on the EV-302/KEYNOTE-A39 tr...
Benchmarking free energy computational methods for revealing the key interactions driving PARP1 selective inhibition.
e13004 Background: Accurately predicting inhibitor selectivity among closely related protein paralogues remains a central...
General population interest in multi-cancer early detection (MCED) testing: Insights from a seven-country survey on drivers of engagement and cross-national differences.
e22507 Background: Most cancers lack organized screening programs, and limited access to primary care further hampers earl...
Preoperative assessment of peritoneal carcinomatosis with [ <sup>68</sup> Ga]Ga-FAPI-46 PET/CT.
5553 Background: Accurate preoperative mapping of peritoneal carcinomatosis (PC) is essential for selecting patients for c...
Application of long-read sequencing to resolve cryptic genomic instability across cancer types.
3067 Background: Computational mutational signatures can identify tumors with homologous recombination deficiency (HRD), m...
Association of routine electronic symptom monitoring with reduced opioid use in patients with head and neck cancers.
1579 Background: Patient reported outcomes (PROs) have become increasingly important in modern healthcare. Head/neck cance...
Baseline peripheral blood absolute lymphocyte count and survival outcomes in patients with PD-L1-positive advanced gastric cancer treated with immune checkpoint inhibitor plus chemotherapy.
e16075 Background: Tumor PD-L1 expression guides the use of immune checkpoint inhibitor (ICI) plus chemotherapy in advance...
Association of vitamin D deficiency with risk in multiple myeloma: A real-world cohort analysis.
e19543 Background: Multiple myeloma (MM) is a plasma cell malignancy characterized by immune dysfunction and end-organ dam...
Score evaluation and prevalence of Her2 status in pleural mesothelioma (PM): MESOHER study.
e20066 Background: Tumors that overexpress HER2 have been historically associated with poorer survival compared with HER2-...
Real-world outcomes of tarlatamab across small cell carcinoma subtypes, including transformed and non-lung primary.
e23350 Background: Tarlatamab, a bispecific antibody targeting delta-like ligand-3 and CD3, has been approved for small ce...
Rare forms of endometrial cancer: Growth factor levels in tumor tissue and patient serum.
e17623 Background: The pathogenesis of uterine serous carcinoma (USC) and clear cell carcinoma (CCC) is not well understoo...
Efficacy of multimodal thermal therapy combined with immune checkpoint inhibitors and chemotherapy in unresectable pancreatic cancer with liver metastases.
4209 Background: Treatment of pancreatic cancer with liver metastasis (PCLM) remains extremely challenging. Multimodal the...
Neoadjuvant immunotherapy in combination with chemotherapy in resectable locally advanced head and neck squamous cell carcinoma: Updated efficacy and safety data from a randomized phase II trial.
6091 Background: Neoadjuvant immunotherapy combined with chemotherapy is a promising strategy for resectable LAHNSCC. Whil...
Early ovarian cancer detection with a multiomic liquid biopsy.
e17563 Background: Ovarian cancer is associated with one of the highest mortality rates among gynecologic malignancies. Ho...
Wearable-derived physical activity monitoring with AI-based detection of treatment-related adverse events during neoadjuvant chemotherapy for early breast cancer: TRACK-BC.
1631 Background: Neoadjuvant chemotherapy (NAC) for early breast cancer (EBC) is commonly delivered in the outpatient sett...
High acceptance of trained scent detection dogs for postoperative surveillance among cancer survivors: A prospective survey on willingness, motivators, and barriers.
e23184 Background: Canine olfaction can detect cancer-specific volatile organic compounds (VOCs) with high accuracy, yet i...
Event-free survival from the randomized phase 2 neoHIP trial evaluating neoadjuvant taxane, HER2-targeted therapy, +/- pembrolizumab in early-stage HER2-positive breast cancer.
623 Background: In early-stage HER2–positive breast cancer, achieving a pathological complete response (pCR) after neoadju...